At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 40 enrolled
Drug / intervention
Vildagliptindrug
Likely dose
Vildagliptin 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Open-label, Interventional Study to Assess the HbA1c Change an 24-hr Glucose Fluctuation After Vildagliptin Plus Metformain (SPC) Treatment in Metformin Monotherapy Uncontrolled Type 2 Diabetes Mellitus Patients
In Brief
A Phase 4 clinical trial evaluating Vildagliptin for Diabetes Mellitus, Type 2. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study will assess the efficacy of vildagliptin plus metformin (SPC) treatment in type 2 diabetes mellitus patients uncontrolled by metformin monotherapy after 24 weeks treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesTaiwan
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 2012
Enrollment StartApr 2013
Primary CompletionSep 2015
TodayJul 2026
First PostedApr 20, 2012
Enrollment StartApr 1, 2013
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 14.2 years ago
Interventions
Vildagliptindrug
Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)